What is the target outcome here? Well that depends, the ideal target outcome for us to live happily ever after would be for them to sell the Perkinamine to Large system suppliers and create next generation devices to drive the market and become larger than IBM, Intel and Google.
Yeh right.
Then we have reality, IMO what will happen is that as soon they have enough data on Perkinamine that is repeatable, verifiable and predictable AND that information is in the hands of MORE than one fortune 500 (that will lose market share to new devices) then the takeover games will begin. How long that will be is anyone’s guess, we’ve been waiting years for it to happen. They are very close now, but as Buzzy points out we have been very close a number of times. In the past though it would take them weeks to make a batch then send it to a university to characterize then they’d put it in their testing pipeline wait for a few more months only to have them request a tweak. By the time the next batch was made and sent off to a university, or Photon X, or Teng, blah blah blah. Honestly I guess that it would be hard for any Fortune 500 to take us serious with those lengthy delays. Finally they now have the ability to produce a batch and test it the next day in a controlled environment within the same building by the same people. It is very small, very fast and very complex, for example The Perkinamine NR the All optical variety does it’s thing in a fempto second. Hard to comprehend a femtosecond is to a second what a second is to 31 million years. 31 Million years ago was before the internet or global warming and 4 foot penguins ruled New Zealand. Oh wait Nebraska was a desert then, um, hmmm,
The best way to try and value this is to think of biotech drug that is in final testing with the potential to cure multiple ailments like aspirin and have as many uses as Gore-Tex. In fact there are so many uses that for years they had trouble focusing on one specific use and consequently ended up being spread too thin. It appears that the Admiral is correcting that, they are much more focused and IMO companies that don’t step up now will be pushed to the side until one does.
How to value it, who the heck knows, a single use is proly worth 5 bucks a share, others 20 bucks not sure if you add them up or just how that works, do they sell licensing for a single use to multiple companies or license one variety to a single company, I Dunno
IMO soon enough the games will begin Joe Miller (Former Corning SVP) and Fred Leonberger (former JDSU cat) have PLENTY of experience in this area, it is not their first time around the block, I’m sure they flew in a corporate jet numerous time to sit across the table from small companies like this and they of all people understand the potential and how to value this technology so IMO we are in good hands.
IMO when the conference call happens we’ll know more. Typically this company does very little in the way of Investor Relations, I’m curious how did you find out about them?
